-
Je něco špatně v tomto záznamu ?
Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study
F. Lohrmann, M. Hufnagel, M. Kunze, B. Afshar, R. Creti, A. Detcheva, J. Kozakova, J. Rodriguez-Granger, UBS. Sørensen, I. Margarit, D. Maione, D. Rinaudo, G. Orefici, J. Telford, M. de la Rosa Fraile, M. Kilian, A. Efstratiou, R. Berner, P....
Jazyk angličtina Země Německo
Typ dokumentu multicentrická studie, časopisecké články
Grantová podpora
DFG 413517907
IMM-PACT stipend
200481
Seventh Framework Programme
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-02-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- antibiotická profylaxe škodlivé účinky MeSH
- infekční komplikace v těhotenství * diagnóza epidemiologie MeSH
- kojenec MeSH
- lidé MeSH
- novorozenec MeSH
- Streptococcus agalactiae MeSH
- streptokokové infekce * diagnóza epidemiologie prevence a kontrola MeSH
- těhotenství MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- novorozenec MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
PURPOSE: Group B streptococcus (GBS) remains a leading cause of invasive disease, mainly sepsis and meningitis, in infants < 3 months of age and of mortality among neonates. This study, a major component of the European DEVANI project (Design of a Vaccine Against Neonatal Infections) describes clinical and important microbiological characteristics of neonatal GBS diseases. It quantifies the rate of antenatal screening and intrapartum antibiotic prophylaxis among cases and identifies risk factors associated with an adverse outcome. METHODS: Clinical and microbiological data from 153 invasive neonatal cases (82 early-onset [EOD], 71 late-onset disease [LOD] cases) were collected in eight European countries from mid-2008 to end-2010. RESULTS: Respiratory distress was the most frequent clinical sign at onset of EOD, while meningitis is found in > 30% of LOD. The study revealed that 59% of mothers of EOD cases had not received antenatal screening, whilst GBS was detected in 48.5% of screened cases. Meningitis was associated with an adverse outcome in LOD cases, while prematurity and the presence of cardiocirculatory symptoms were associated with an adverse outcome in EOD cases. Capsular-polysaccharide type III was the most frequent in both EOD and LOD cases with regional differences in the clonal complex distribution. CONCLUSIONS: Standardizing recommendations related to neonatal GBS disease and increasing compliance might improve clinical care and the prevention of GBS EOD. But even full adherence to antenatal screening would miss a relevant number of EOD cases, thus, the most promising prophylactic approach against GBS EOD and LOD would be a vaccine for maternal immunization.
Department of Biomedicine Health Aarhus University Aarhus Denmark
Department of Infectious Diseases Istituto Superiore Di Sanità Rome Italy
National Center of Infectious and Parasitic Diseases Sofia Bulgaria
National Institute of Public Health Prague Czech Republic
Servicio Andaluz de Salud Hospital Universitario Virgen de Las Nieves Granada Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016786
- 003
- CZ-PrNML
- 005
- 20231026105539.0
- 007
- ta
- 008
- 231013s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s15010-022-01965-x $2 doi
- 035 __
- $a (PubMed)36547864
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Lohrmann, Florens $u Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany $u Spemann Graduate School of Biology and Medicine (SGBM), Faculty of Biology, University of Freiburg and IMM-PACT Clinician Scientist Program, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- 245 10
- $a Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study / $c F. Lohrmann, M. Hufnagel, M. Kunze, B. Afshar, R. Creti, A. Detcheva, J. Kozakova, J. Rodriguez-Granger, UBS. Sørensen, I. Margarit, D. Maione, D. Rinaudo, G. Orefici, J. Telford, M. de la Rosa Fraile, M. Kilian, A. Efstratiou, R. Berner, P. Melin, DEVANI Study Group
- 520 9_
- $a PURPOSE: Group B streptococcus (GBS) remains a leading cause of invasive disease, mainly sepsis and meningitis, in infants < 3 months of age and of mortality among neonates. This study, a major component of the European DEVANI project (Design of a Vaccine Against Neonatal Infections) describes clinical and important microbiological characteristics of neonatal GBS diseases. It quantifies the rate of antenatal screening and intrapartum antibiotic prophylaxis among cases and identifies risk factors associated with an adverse outcome. METHODS: Clinical and microbiological data from 153 invasive neonatal cases (82 early-onset [EOD], 71 late-onset disease [LOD] cases) were collected in eight European countries from mid-2008 to end-2010. RESULTS: Respiratory distress was the most frequent clinical sign at onset of EOD, while meningitis is found in > 30% of LOD. The study revealed that 59% of mothers of EOD cases had not received antenatal screening, whilst GBS was detected in 48.5% of screened cases. Meningitis was associated with an adverse outcome in LOD cases, while prematurity and the presence of cardiocirculatory symptoms were associated with an adverse outcome in EOD cases. Capsular-polysaccharide type III was the most frequent in both EOD and LOD cases with regional differences in the clonal complex distribution. CONCLUSIONS: Standardizing recommendations related to neonatal GBS disease and increasing compliance might improve clinical care and the prevention of GBS EOD. But even full adherence to antenatal screening would miss a relevant number of EOD cases, thus, the most promising prophylactic approach against GBS EOD and LOD would be a vaccine for maternal immunization.
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a Streptococcus agalactiae $7 D013292
- 650 12
- $a streptokokové infekce $x diagnóza $x epidemiologie $x prevence a kontrola $7 D013290
- 650 _2
- $a antibiotická profylaxe $x škodlivé účinky $7 D019072
- 650 12
- $a infekční komplikace v těhotenství $x diagnóza $x epidemiologie $7 D011251
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hufnagel, Markus $u Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany
- 700 1_
- $a Kunze, Mirjam $u Department for Gynecology and Obstetrics, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany
- 700 1_
- $a Afshar, Baharak $u UK Health Security Agency GB, London, UK
- 700 1_
- $a Creti, Roberta $u Department of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy
- 700 1_
- $a Detcheva, Antoaneta $u National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
- 700 1_
- $a Kozakova, Jana $u National Institute of Public Health, Prague, Czech Republic
- 700 1_
- $a Rodriguez-Granger, Javier $u Servicio Andaluz de Salud, Hospital Universitario Virgen de Las Nieves, Granada, Spain
- 700 1_
- $a Sørensen, Uffe B Skov $u Department of Biomedicine, Health, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Margarit, Immaculada $u GSK, Siena, Italy
- 700 1_
- $a Maione, Domenico $u GSK, Siena, Italy
- 700 1_
- $a Rinaudo, Daniela $u GSK, Siena, Italy
- 700 1_
- $a Orefici, Graziella $u Department of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy
- 700 1_
- $a Telford, John $u GSK, Siena, Italy
- 700 1_
- $a de la Rosa Fraile, Manuel $u Servicio Andaluz de Salud, Hospital Universitario Virgen de Las Nieves, Granada, Spain
- 700 1_
- $a Kilian, Mogens $u Department of Biomedicine, Health, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Efstratiou, Androulla $u UK Health Security Agency GB, London, UK
- 700 1_
- $a Berner, Reinhard $u Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- 700 1_
- $a Melin, Pierrette $u Department of Clinical Microbiology, National Reference Center Streptococcus agalactiae, University Hospital Center of Liege, Avenue de L'Hôpital, 1, 4000, Liège 1, Belgique. Pierrette.Melin@uliege.be $1 https://orcid.org/0000000221595774
- 710 2_
- $a DEVANI Study Group
- 773 0_
- $w MED00002234 $t Infection $x 1439-0973 $g Roč. 51, č. 4 (2023), s. 981-991
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36547864 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105533 $b ABA008
- 999 __
- $a ok $b bmc $g 2000368 $s 1203148
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 51 $c 4 $d 981-991 $e 20221222 $i 1439-0973 $m Infection $n Infection $x MED00002234
- GRA __
- $a DFG 413517907 $p IMM-PACT stipend
- GRA __
- $a 200481 $p Seventh Framework Programme
- LZP __
- $a Pubmed-20231013
